Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00789555 · ClinicalTrials.gov registry record · Phase 4
Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis
A Phase 4 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,260
- Enrollment target
NCT00789555 is a Phase 4 study that has completed, run by Alcon Research. The registered enrollment target is 1,260 participants.
The verdict
NCT00789555, a Phase 4 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,260 participants
- Enrollment target
Study Summary
The purpose of this study was to assess local nasal adverse effects, as well as systemic effects, of PATANASE nasal spray when compared with Patanase Vehicle, pH 3.7 and Patanase Vehicle, pH 7.0 in patients with perennial allergic rhinitis (PAR).
Interventions
- DRUG Olopatadine hydrochloride 0.6% nasal spray (PATANASE)
- OTHER Olopatadine nasal spray vehicle, pH 3.7
- OTHER Olopatadine nasal spray vehicle, pH 7.0
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,260 participants |
| Start Date | 2008-11 |
| Est. Completion | 2011-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00789555
The ClinicalTrials.gov registry entry for NCT00789555 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Olopatadine hydrochloride 0.6% nasal spray (PATANASE) is the first listed.
NCT00789555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00789555 about?
NCT00789555 is a clinical study titled "Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis". The purpose of this study was to assess local nasal adverse effects, as well as systemic effects, of PATANASE nasal spray when compared with Patanase Vehicle, pH 3.7 and Patanase Vehicle, pH 7.0 in patients with perennial allergic rhinitis (PAR).
What is the current status of trial NCT00789555?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,260 participants. The study started on 2008-11. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00789555?
The interventions under investigation include: Olopatadine hydrochloride 0.6% nasal spray (PATANASE) (DRUG), Olopatadine nasal spray vehicle, pH 3.7 (OTHER), Olopatadine nasal spray vehicle, pH 7.0 (OTHER).
Who is sponsoring clinical trial NCT00789555?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.